StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HIT$1.03+3.83%
Fair $1.03+0.0%

HIT

Health In Tech, Inc.

Technology / Software - ApplicationNasdaqCM

$1.03

+0.04 (+3.83%)

Fairly Valued+0.0%Fair Value $1.03Fund rank 26/100 · Data gapFallback financials|
SA 56/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $384517.00 · quality 45.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

56/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · HITLocal privado en este navegador · Health In Tech, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$68M

P/E

51.5x

↑

EV/EBITDA

20.2x

↑

ROE

7.5%

↑

Gross Margin

62.8%

↑

Debt/Equity

0.01

↓
52-Week Range$1
$1$4

TradingView lightweight chart

HIT price, volumen y niveles de valoración

Último $1.030Periodo -79.8%
Fair value: $1.030

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+79.4%

FCF CAGR

—

FCF margin

-0.2%

FCF / Net income

-0.04x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $33.3M · net income $1.3M · FCF $-56108.0

2022-FY → 2025-FY

Gross margin

62.8%-31.4% pts

Operating margin

4.6%+1.0% pts

Net margin

3.8%+2.5% pts

FCF margin

-0.2%+7.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$33.3M$33.3M$19.5M$19.2M$5.8M
Net Income$1.3M$1.3M$670477.00$2.5M$79742.00
EBITDA$2.6M$2.6M$1.9M$3.8M$205582.00
EPS0.020.020.010.050.00
Gross Margin62.8%62.8%79.2%88.0%94.2%
Operating Margin4.6%4.6%5.1%17.7%3.6%
Net Margin3.8%3.8%3.4%12.9%1.4%
Balance Sheet
Debt/Equity0.010.010.020.310.30
Current Ratio3.133.13———
Cash Flow
Free Cash Flow$-56108.00$-56108.00$1.3M$384517.00$-436627.00
Returns
ROE7.5%7.5%5.1%40.6%7.6%
Valuation
P/E51.5051.50435.00——
EV/EBITDA20.1720.17147.52——
P/B3.483.4822.15——
Growth & Yield
Revenue Growth71.0%71.0%1.8%231.9%—
EPS Growth62.9%62.9%-73.2%3005.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

65.9%

muy exigente

EPS terminal req.

$0.09

Spread vs growth

-3.0%

5Y implied EPS CAGR

40.8%

muy exigente

EPS terminal req.

$0.11

Spread vs growth

22.1%

10Y implied EPS CAGR

24.4%

exigente

EPS terminal req.

$0.18

Spread vs growth

38.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +68.9%

Total return

+68.9%

Start / end P/E

49.7x → 51.5x

EPS bridge

0.01 → 0.02

Residual

+2.3%

EPS growth+62.9%
Multiple rerating+3.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term+2.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.